Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2

Completed · Phase 2

Conditions studied: Colorectal Cancer

In brief

Phase II trial to study the effectiveness of the monoclonal antibody trastuzumab and chemotherapy with irinotecan in treating patients who have stage IV colorectal cancer that overexpresses HER2. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.

Key facts

Study ID

NCT00003995

Run by

National Cancer Institute (NCI)

People needed

32

Starts

1999-09-01

Last updated by the study team

2013-02-08

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Albert Einstein Comprehensive Cancer Center — The Bronx, New York, United States
• University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
• Lifespan: The Miriam Hospital — Providence, Rhode Island, United States
• Sarah Cannon-Minnie Pearl Cancer Center — Nashville, Tennessee, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.